Flow cytometry is a powerful technology for investigating questions related to the immune response and its sustenance, as well as detailed mechanisms of COVID-19. Simplified cell-based and biomarker-based strategies can provide rapid insights into these aspects of the disease, and the evaluation of anti-SARS-CoV-2 antibodies and their isotypes has become a crucial aspect of COVID-19 research, supporting the development and understanding of vaccine-based strategies. In this webinar, we discuss the results from a new flow cytometry-based assay—the Guava® SARS-CoV-2 Multi-Antigen Antibody Assay. This multiplex, bead-based assay detects the presence of IgG, IgM, and IgA antibodies against multiple SARS-CoV-2 antigens, including the nucleocapsid protein, the receptor-binding domain of the spike protein, and the S1 subunit of the spike protein, with high detection sensitivity. Although the assay was optimized on Luminex’s Guava® Platforms, it can be used on any flow cytometer equipped with either a 488 nm or 532 nm laser. We also review data from longitudinal studies, as well as data from vaccinated donors and serological samples from natural infection taken at different durations post-symptom onset. Finally, the capabilities of flow cytometry platforms to provide important immune cell information will also be discussed.
For Research Use Only. Not for use on diagnostic procedures.
1. Value of multi-antigen approaches for detection of SARS-CoV-2 antibodies.
2. Importance of the study of SARS-CoV-2 antibody isotypes in SARS-CoV-2 research.
3. Continued importance of serology in natural infection and vaccine research.